Skip to main content

Potent Adenosine A1 and A2A Receptors Antagonists: Recent Developments

Buy Article:

$55.00 plus tax (Refund Policy)

This review summarizes the current tendencies observed in the past 5 years in the development of A1 and A2A adenosine receptor antagonists performed in various academia and industry. A1 and A2A AR antagonists are as well xanthines as heteroaromatic derivatives and are most commonly 6:5 fused heteroatomic compounds.

Among xanthine-based compounds, some common features could be pointed out. The recent A1 AR ligands which show good biological profile, possess long alkyl chains in position 1 and 3 as well as bulky C(8)- substituent, while A2A AR antagonists with a high A2A AR affinity are C(8)-styryl substituted with N(1)- alkyl/alkynyl moiety or fused tricyclic xanthines possessing heteroatom(s) in the third cycle.

The research in the field of heteroaromatic A1 and A2A ARs antagonists impressively has a wide range. Ligands are as well non-fused monocyclic substituted compounds as fused bi- and tricyclic derivatives with the nitrogen, oxygen and sulfur heteroatoms. Most often, adenosine A1 receptor non-xanthine antagonists are adenine-based, having substituted amino group and variable nitrogen atoms positions in the molecules. A2A AR ligands show good affinity when furanyl function, which is crucial for binding, is present in the fused bicyclic and tricyclic analogs. Moreover, tricyclic nitrogen containing antagonists in order to be active, frequently possess long-alkylphenyl moiety.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: A1 Adenosine receptor antagonists; A2A Adenosine receptor antagonists; Nitrogen (poly)heterocyclic compounds; Xanthine derivatives

Document Type: Research Article

Affiliations: Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University;Medyczna 9; 30-688 Krakow; Poland.

Publication date: 2006-12-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more